263 related articles for article (PubMed ID: 24341880)
1. Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy.
Calvi A; De Riz M; Pietroboni AM; Ghezzi L; Maltese V; Arighi A; Fumagalli GG; Jacini F; Donelli C; Comi G; Galimberti D; Scarpini E
Immunotherapy; 2014; 6(1):23-8. PubMed ID: 24341880
[TBL] [Abstract][Full Text] [Related]
2. Immunological and clinical consequences of treating a patient with natalizumab.
Schwab N; Höhn KG; Schneider-Hohendorf T; Metz I; Stenner MP; Jilek S; Du Pasquier RA; Gold R; Meuth SG; Ransohoff RM; Brück W; Wiendl H
Mult Scler; 2012 Mar; 18(3):335-44. PubMed ID: 21908480
[TBL] [Abstract][Full Text] [Related]
3. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
[TBL] [Abstract][Full Text] [Related]
4. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
[TBL] [Abstract][Full Text] [Related]
5. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
[TBL] [Abstract][Full Text] [Related]
6. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
[TBL] [Abstract][Full Text] [Related]
7. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
[TBL] [Abstract][Full Text] [Related]
8. JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment.
Schippling S; Kempf C; Büchele F; Jelcic I; Bozinov O; Bont A; Linnebank M; Sospedra M; Weller M; Budka H; Martin R
Ann Neurol; 2013 Oct; 74(4):622-6. PubMed ID: 23868420
[TBL] [Abstract][Full Text] [Related]
9. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
[TBL] [Abstract][Full Text] [Related]
10. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
11. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
Aly L; Yousef S; Schippling S; Jelcic I; Breiden P; Matschke J; Schulz R; Bofill-Mas S; Jones L; Demina V; Linnebank M; Ogg G; Girones R; Weber T; Sospedra M; Martin R
Brain; 2011 Sep; 134(Pt 9):2687-702. PubMed ID: 21908874
[TBL] [Abstract][Full Text] [Related]
12. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
13. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
[TBL] [Abstract][Full Text] [Related]
14. Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
Tan LA; Lopes DK
J Clin Neurosci; 2015 Oct; 22(10):1669-71. PubMed ID: 26115897
[TBL] [Abstract][Full Text] [Related]
15. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
16. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy - immune reconstitution inflammatory syndrome (PML-IRIS) in liver transplant recipient.
Avsenik J; Horvat Ledinek A; Šurlan Popovič K
Mult Scler Relat Disord; 2017 Oct; 17():135-137. PubMed ID: 29055444
[TBL] [Abstract][Full Text] [Related]
18. Advances in the management of PML: focus on natalizumab.
Fox R
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Hodel J; Bapst B; Outteryck O; Verclytte S; Deramecourt V; Benadjaoud MA; Pruvo JP; Vermersch P; Leclerc X
Mult Scler; 2018 Dec; 24(14):1902-1908. PubMed ID: 29343163
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
